Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease.

ABSTRACT: Alzheimer's disease (AD) and Parkinson's disease (PD) are the first and second most common neurodegenerative disorders, respectively. Both are proteinopathies with inexorable courses and no approved disease-modifying therapies. A substantial effort has been made to identify interventions that could slow down the progression of AD and PD; to date, with no success. The advances in biomarker research improved the identification of individuals at risk for these disorders before symptom onset, recognizing the pre-clinical stage, in which there is abnormal protein accumulation but no clinical symptoms of the disease, and the prodromal stage, in which mild symptoms are present but the clinical diagnostic criteria for disease cannot be fulfilled. The ability to detect pre-clinical and prodromal st

SUBMITTER: de Aquino CH 

PROVIDER: S-EPMC8377160 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature